Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis

David W Denning, Kieren A Marr, Wendi M Lau, David P Facklam, Voravit Ratanatharathorn, Cornelia Becker, Andrew J Ullmann, Nita L Seibel, Patricia M Flynn, Jo-Anne H van Burik, Donald N Buell, Thomas F Patterson, David W Denning, Kieren A Marr, Wendi M Lau, David P Facklam, Voravit Ratanatharathorn, Cornelia Becker, Andrew J Ullmann, Nita L Seibel, Patricia M Flynn, Jo-Anne H van Burik, Donald N Buell, Thomas F Patterson

Abstract

Background: Micafungin (FK463) is a new lipopeptide compound (echinocandin) with activity against Aspergillus and Candida species. This study evaluated the safety and efficacy of micafungin in patients with proven or probable invasive aspergillosis (IA).

Methods: A multinational, non-comparative study was conducted to examine proven or probable (pulmonary only) Aspergillus species infection in a wide variety of patient populations. The study employed an open-label design utilizing micafungin alone or in combination with another systemic antifungal agent. Criteria for IA and therapeutic responses were judged by an independent panel.

Results: Of the 331 patients enrolled, only 225 met diagnostic criteria for IA as determined by the independent panel and received at least one dose of micafungin. Patients included 98/225 who had undergone hematopoietic stem cell transplantation (HSCT) (88/98 allogeneic), 48 with graft versus host disease (GVHD), and 83/225 who had received chemotherapy for hematologic malignancy. A favorable response rate at the end of therapy was seen in 35.6% (80/225) of patients. Of those only treated with micafungin, favorable responses were seen in 6/12 (50%) of the primary and 9/22 (40.9%) of the salvage therapy group, with corresponding numbers in the combination treatment groups of 5/17 (29.4%) and 60/174 (34.5%) of the primary and salvage treatment groups, respectively. Of the 326 micafungin-treated patients, 183 (56.1%) died during therapy or in the 6-week follow-up phase; 107 (58.5%) deaths were attributable to IA.

Conclusions: Micafungin as primary or salvage therapy proved efficacious and safe in high-risk patients with IA, although patient numbers are small in the micafungin-only groups.

References

    1. Cornet M., Fleury L., Maslo C., Bernard J.F., Brucker G. Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J Hosp Infect. 2002;51:288–296.
    1. Jantunen E., Salonen J., Juvonen E., Koivunen E., Siitonen T., Lehtinen T., et al. Invasive fungal infections in autologous stem cell transplant recipients: a nation-wide study of 1188 transplanted patients. Eur J Haematol. 2004;73:174–178.
    1. Junghanss C., Marr K.A., Carter R.A., Sandmaier B.M., Maris M.B., Maloney D.G., et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant. 2002;8:512–520.
    1. Daly A., McAfee S., Dey B., Colby C., Schulte L., Yeap B., et al. Nonmyeloablative bone marrow transplantation: infectious complications in 65 recipients of HLA-identical and mismatched transplants. Biol Blood Marrow Transplant. 2003;9:373–382.
    1. Marr K.A., Patterson T., Denning D. Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am. 2002;16:875–894. vi.
    1. Grow W.B., Moreb J.S., Roque D., Manion K., Leather H., Reddy V., et al. Late onset of invasive Aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant. 2002;29:15–19.
    1. Singh N., Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant. 2003;22:258–266.
    1. Minari A., Husni R., Avery R.K., Longworth D.L., DeCamp M., Bertin M., et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis. 2002;4:195–200.
    1. Duchini A., Redfield D.C., McHutchison J.G., Brunson M.E., Pockros P.J. Aspergillosis in liver transplant recipients: successful treatment and improved survival using a multistep approach. South Med J. 2002;95:897–899.
    1. Libanore M., Prini E., Mazzetti M., Barchi E., Raise E., Gritti F.M., et al. Invasive aspergillosis in Italian AIDS patients. Infection. 2002;30:341–345.
    1. Valles J., Mesalles E., Mariscal D., del Mar F.M., Pena R., Jimenez J.L., et al. A 7-year study of severe hospital-acquired pneumonia requiring ICU admission. Intensive Care Med. 2003;29:1981–1988.
    1. Meersseman W., Vandecasteele S.J., Wilmer A., Verbeken E., Peetermans W.E., Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med. 2004;170:621–625.
    1. Dimopoulos G., Piagnerelli M., Berre J., Eddafali B., Salmon I., Vincent J.L. Disseminated aspergillosis in intensive care unit patients: an autopsy study. J Chemother. 2003;15:71–75.
    1. Agusti C., Rano A., Filella X., Gonzalez J., Moreno A., Xaubet A., et al. Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response. Chest. 2003;123:488–498.
    1. Jacobsohn D.A., Hallick J., Anders V., McMillan S., Morris L., Vogelsang G.B. Infliximab for steroid-refractory acute GVHD: a case series. Am J Hematol. 2003;74:119–214.
    1. Wang H.J., Ding Y.Q., Xu J., Li X., Li X.F., Yang L., et al. Death of a SARS case from secondary Aspergillus infection. Chin Med J (Engl) 2004;117:1278–1280.
    1. Denning D.W. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis. 1996;23:608–615.
    1. Patterson T.F., Kirkpatrick W.R., White M., Hiemenz J.W., Wingard J.R., Dupont B., et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. Medicine (Baltimore) 2000;79:250–260.
    1. Lin S.J., Schranz J., Teutsch S.M. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001;32:358–366.
    1. Denning D.W. Echinocandin antifungal drugs. Lancet. 2003;362:1142–1151.
    1. Higashiyama Y., Kohno S. Micafungin: a therapeutic review. Expert Rev Anti Infect Ther. 2004;2:345–355.
    1. Ikeda F., Wakai Y., Matsumoto S., Maki K., Watabe E., Tawara S., et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother. 2000;44:614–618.
    1. Matsumoto S., Wakai Y., Nakai T., Hatano K., Ushitani T., Ikeda F., et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob Agents Chemother. 2000;44:619–621.
    1. Warn P.A., Morrissey G., Morrissey J., Denning D.W. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. J Antimicrob Chemother. 2003;51:913–919.
    1. Chandrasekar P.H., Cutright J.L., Manavathu E.K. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis. Clin Microbiol Infect. 2004;10:925–928.
    1. Stevens D.A. Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy (San Francisco) American Society for Microbiology; Washington, DC: 1999. Drug interaction in vitro between a polyene (AmBisome: AmBi) and an echinocandin (FK463:FK) vs Aspergillus species. [abstract J-151]
    1. Kohno S., Maesaki S., Iwakawa J., Miyazaki Y., Nakamura K., Kakeya H., et al. Program and abstracts of the 40th interscience conference on antimicrobial agents and chemotherapy (Toronto) American Society for Microbiology; Washington, DC: 2000. Synergistic effects of combination of FK463 with amphotericin B: enhanced efficacy in murine model of invasive pulmonary aspergillosis. [abstract J-1686]
    1. Nakajima M., Tamada S., Yoshida K., Wakai Y., Nakai T., Ikeda F., et al. Program and abstracts of the 40th interscience conference on antimicrobial agents and chemotherapy (Toronto) American Society for Microbiology; Washington, DC: 2000. Pathological findings in a murine pulmonary aspergillosis model: treatment with FK463, amphotericin B and a combination of FK463 and amphotericin B. [abstract J-1685]
    1. Petraitis V., Petraitiene R.J., Leguit R.J., Candelario M., Sein T., Peter J., et al. Program and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy (San Francisco) American Society for Microbiology; Washington, DC: 1999. Combination antifungal therapy with FK463 plus amphotericin B in treatment of experimental pulmonary aspergillosis. [abstract J-2003]
    1. Powles R., Sirohi B., Chopra R., Russel N., Prentice H.G., et al. Program and abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy (Chicago) American Society for Microbiology; Washington, DC: 2001. Assessment of maximum tolerated dose (MTD) of FK463 in cancer patients undergoing haematopoetic stem cell transplantation. [abstract J-676]
    1. Pettengell K., Mynhardt J., Kluyts T., Lau W., Facklam D., Buell D. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther. 2004;20:475–481.
    1. Hiemenz J., Cagnoni P., Simpson D., Devine S., Chao N., Keirns J., et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother. 2005;49:1331–1336.
    1. Kohno S., Masaoka T., Yamaguchi H., Mori T., Urabe A., Ito A., et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis. 2004;36:373–379.
    1. Maertens J., Raad I., Petrikkos G., Boogaerts M., Selleslag D., Petersen F.B., et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39:1563–1571.
    1. Caillot D., Couaillier J.F., Bernard A., Casasnovas O., Denning D.W., Mannone L., et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol. 2001;19:253–259.
    1. Denning D.W., Lee J.Y., Hostetler J.S., Pappas P., Kauffman C.A., Dewsnup D.H., et al. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med. 1994;97:135–144.
    1. Bowden R., Chandrasekar P., White M.H., Li X., Pietrelli L., Gurwith M., et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis. 2002;35:359–366.
    1. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.W., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408–415.
    1. Denning D.W., Ribaud P., Milpied N., Caillot D., Herbrecht R., Thiel E., et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34:563–571.
    1. Steinbach W.J., Stevens D.A., Denning D.W. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis. 2003;37(Suppl. 3):S188–S224.
    1. Denning D.W., Stevens D.A. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis. 1990;12:1147–1201.
    1. Johnson M.D., MacDougall C., Ostrosky-Zeichner L., Perfect J.R., Rex J.H. Combination antifungal therapy. Antimicrob Agents Chemother. 2004;48:693–715.
    1. Ratanatharathorn V. American Society of Hematology 44th annual meeting program and abstracts (Philadelphia) The American Society of Hematology; Washington, DC: 2002. Micafungin in combination with systemic antifungal agents in the treatment of refractory aspergillosis (RA) in bone marrow transplant (BMT) patients. [abstract 2472]
    1. Kontoyiannis D.P., Hachem R., Lewis R.E., Rivero G.A., Torres H.A., Thornby J., et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003;98:292–299.
    1. Choi J.H., Brummer E., Stevens D.A. Combined action of micafungin, a new echinocandin, and human phagocytes for antifungal activity against Aspergillus fumigatus. Microbes Infect. 2004;6:383–389.
    1. Graybill J.R., Bocanegra R., Gonzalez G.M., Najvar L.K. Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. J Antimicrob Chemother. 2003;52:656–662.
    1. Petraitis V., Petraitiene R., Sarafandi A.A., Kelaher A.M., Lyman C.A., Casler H.E., et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis. 2003;187:1834–1843.
    1. Chiou C.C., Mavrogiorgos N., Tillem E., Hector R., Walsh T.J. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob Agents Chemother. 2001;45:3310–3321.
    1. Fukuda T., Boeckh M., Carter R.A., Sandmaier B.M., Maris M.B., Maloney D.G., et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood. 2003;102:827–833.
    1. de Wet N., Llanos-Cuentas A., Suleiman J., Baraldi E., Krantz E.F., Della N.M., et al. A randomized, double-blind, parallel-group, dose–response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis. 2004;39:842–849.
    1. de Wet N.T.E., Bester A.J., Viljoen J.J., Filho F., Suleiman J.M., Ticona E., et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther. 2005;21:899–907.
    1. Buell D., Kovanda L., Drake T., Fisco C. Program and abstracts of the 45th interscience conference on antimicrobial agents and chemotherapy (Washington, DC) American Society for Microbiology; Washington, DC: 2005. Alternative day dosing of micafungin in the treatment of esophageal candidiasis. [abstract M-719]
    1. Ostrosky-Zeichner L., Kontoyiannis D., Raffalli J., Mullane K.M., Vazquez J., Anaissie E.J., et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis. 2005;24:654–661.
    1. Ruhnke M., Kuse E., Chetchotisakd P., Arns Da Cunha C., Diekmann-Berndt H., et al. Program and abstracts of the 45th interscience conference on antimicrobial agents and chemotherapy (Washington, DC) American Society for Microbiology; Washington, DC: 2005. Comparison of micafungin and liposomal amphotericin B for invasive candidiasis. [abstract M-722c-2005]
    1. van Burik J.A., Ratanatharathorn V., Stepan D.E., Miller C.B., Lipton J.H., Vesole D.H., et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis. 2004;39:1407–1416.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi